Emcure Pharmaceuticals Limited
1,770.40
INR
-12.20
(-0.68%)
Emcure Pharmaceuticals Limited
NSE:EMCURE
(National Stock Exchange of India)
Recent
price
1,770.40
P/E
ratio
34.41
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Emcure Pharmaceuticals Ltd. (EMCURE.NS) develops, manufactures and markets a broad portfolio of pharmaceutical products across major therapeutic areas including gynaecology, cardiology, nephrology, oncology, HIV antivirals, blood-related treatments, anti-infectives, pain and analgesics, diabetes management, respiratory, hormones and anti-diabetics; offers differentiated formulations such as complex generics, biosimilars, vaccines, monoclonal antibodies, orals including tablets, capsules, soft-gelatin capsules and solid orals, injectables, active pharmaceutical ingredients, syrups, eye drops, solutions, ointments and pessaries; leads the Indian market in gynaecology with a 13.53% share and HIV antivirals while ranking as the 13th largest by domestic sales and fourth by market share in covered markets as of FY24. Founded in 1981 and headquartered in Pune, India, at Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, the company operates 13 advanced manufacturing facilities and five state-of-the-art R&D centers across India including US FDA-approved sites at Kurkumbh for APIs, Sanand and Jammu for solids, and a biotech facility at Hinjawadi, plus a manufacturing and R&D center in East Brunswick, New Jersey, USA; sells products in over 70 countries with international revenues at 51.72% of total in FY24, emphasizing strong presence in Europe, Canada, North America, Middle East, APAC and India through its own distribution and alliances with local and multinational partners. In July 2024, Emcure completed its initial public offering on BSE and NSE raising Rs 1,952 crore including a fresh issue of Rs 800 crore for debt repayment and general purposes; in 2025, the company approved acquisition of the remaining 20.42% stake in subsidiary Zuventus Healthcare for Rs 724.9 crore in cash, expected to close by Q2 FY26, enabling full consolidation, operational synergies and strengthened domestic market leadership across multiple therapeutic segments.